Citigroup initiates coverage on Vanda Pharmaceuticals Inc (Nasdaq: VNDA) with a Hold. Price target $25.

Citigroup analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE